MDMA and serotonin: Based on two cases

Actas Espanolas de Psiquiatria

Volumn 33, Issue 5, 2005, Pages 339-342

  Garcia Cabeza I ^a   Zabala, A ^a   Soto Montenegro, M L ^a   Arango, C ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Cognitive disorder; MDMA; Psychopatology; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; PSYCHEDELIC AGENT; SEROTONIN;

ADOLESCENT; ADULT; ARTICLE; BRAIN; CASE REPORT; DRUG ABUSE; DRUG EFFECT; HUMAN; MALE; METABOLISM; PSYCHOSIS;

ADOLESCENT; ADULT; AMPHETAMINE-RELATED DISORDERS; BRAIN; HALLUCINOGENS; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PSYCHOSES, SUBSTANCE-INDUCED; SEROTONIN;

EID: 24344483440     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Shulgin AT, Nichols DE. Characterization of three new psychotomimetics. In: Stillman R, Willette R, editores. The psychopharmacology of hallucinogens. New York: Pergamon Press, 1978; p. 74-83.
2. Memoria Plan Nacional sobre Drogas 2002. Delegación del Gobierno para el Plan Nacional de Drogas. Ministerio del Interior.
3. Recio AI, Rubio G. Epidemiología del consumo de éxtasis y patrones de uso. En: Rubio G, Álamo C, editores. Éxtasis: una droga para la controversia. Valencia: Promolibro, 1988; p. 1-23.
4. Memoria Plan Nacional sobre Drogas 2000. Delegación del Gobierno para el Plan Nacional de Drogas. Ministerio del Interior.
5. Delgado JM. Consumo de drogas y perfil de personalidad en jóvenes de Asturias. Doctoral tesis. Universidad de Oviedo, 2002.
6. McCann UD, Lowe KA, Ricaurte GA. Long-lasting effects of recreational drugs of abuse on the central nervous system. The Neuroscientist 1997;3:399-411.
7. Ricaurte GA, McCann AD. Estudios experimentales sobre la 3,4-metilenodioximetanfetamina (MDMA o «éxtasis») y su capacidad para lesionar las neuronas serotoninérgicas cerebrales. In: Palomo T, Beninger RJ, Jiménez-Arriero MA, Archer T, editors. Trastornos adictivos. En: Madrid: Fundación Cerebro y Mente, 1999; p. 237-58.
8. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS. Biochemical and histological evidence that methytlene-dioxymethamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 1987;241:338-45.
9. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA («ecstasy») on brain serotonin neurons in human beings. Lancet 1998;352:1433-7.
10. Obrocki J, Buchert R, Väterlein O, Thomasius R, Beyer W, Schiemann T. Ecstasy-long-term effects on the human central nervous system revealed by positron emission tomography. Br J Psychiatry 1999;175:186-8.
11. Gamma A, Buck A, Berthold T, Vollenweider FX. No difference in brain activation during cognitive performance between ecstasy (3,4-methytlene- dioxymethemphetamine) users and control subjects: a (H2150)-Positron Emission Tomography Study. J Clin Psychopharmacol 2001;21:66-71.
12. Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA («ecstasy») users. Br J Psychiatry 1999;175:63-9.
13. Chang L, Grob CS, Ernst T, Itti L, Mishkin FS, Jose-Melchor R, et al. Effect of ecstasy (3,4-methytlene-dioxymethemphetamine) on cerebral blood flow: a co-registered SPECT and MRI study. Psychiatry Res 2000;98:15-28.
14. Buchert R, Obrocki J, Thomasius R, Väterlein O, Petersen K, Jeniccke, et al. Long-terms effects of «ecstasy» abuse on the human brain study FDG PET. Nucl Med Comm 2001;22:889-97.
15. Reneman L, Lavaye J, Schamand B, de Wolf FA, van den Brink W, den Heeten GJ, et al. Cortical serotonin transporter density and verbal memory in individuals who stopped using «ecstasy». Arch Gen Psychiatry 2001;58:901-6.
16. Reneman L, Booij J, de Bruin K, Reitsma JB, de Wolf FA, Gunning WB. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ectasy) on brain serotonin neurons. Lancet 2001;358:1864-9.
17. Fox HC, Parrott AC, Turner JJ, Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug. J Psychopharmacol 2001;15(4):273-81.
18. Krystal JH. Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function? Am J Drug Alcohol Abuse 1992;18(3):331-41.
19. Parrott AC, Lasky J. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology (Berl) 1998;139(3):261-8.
20. Bolla KI, McCann UD, Ricaurte GA, Memory impairment in abstinent MDMA («ecstasy») users. Neurology 1998;51(6):1532-7.
21. Morgan MJ. Memory deficits associated with recreational use of «ecstasy» (MDMA). Psychopharmacology (Berl) 1999;141(1):30-6.
22. Gouzoulis-Mayfrank E. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry 2000;68(6):719-25.
23. Rodgers J. Cognitive performance amongst recreational users of «ecstasy». Psychopharmacology (Berl) 2000;151(1):19-24.
24. Verkes RJ. Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology (Berl) 2001;153(2):196-202.
25. Wareing M, Fisk JE, Murphy PN. Working memory deficits in current and previous users of MDMA («ecstasy»). Br J Psychol 2000; 91(Pt 2):181-8.
26. Morgan MJ. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology (Berl) 2000;152(3): 230-48.
27. Fox HC. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA («ecstasy») polydrug users. Psychopharmacology (Berl) 2002;162(2):203-14.
28. McCardle K. Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology (Berl) 2004;173(3-4):434-9.
29. Heffernan TM. Prospective memory, everyday cognitive failure and central executive function in recreational users of Ecstasy. Hum Psychopharmacol 2001;16(8):607-12.
30. Arranz B, Rosel P, Ramírez N, San L. Disfunción genética del receptor de serotonina 5-HT2A en los trastornos psiquiátricos. Actas Esp Psiquiatr 2001;29:131-8.
31. Bango J, Fadón P, Mata F, Rubio G, Santo-Domingo J. Trastornos psiquiátricos y consumo de MDMA (éxtasis): revisión y casos. Actas Luso-Esp Neurol Psiquiatr 1998;26:260-3.
32. Bailly. Neuropsychiatric disorders induced by MDMA. Encephale 1999;25:595-602.
33. McGuire P. Long term psychiatric and cognitive effects of MDMA use. Toxicology Letters 2000;112-3:153-6.
34. Creighton FJ, Black DL, Hyde CE. «Ecstasy» psychosis and flashbacks. Br J Psychiatry 1991;159:713-5.
35. McGuire PK, Fahy T. Chronic paranoid psychosis after misuse of MDMA («ecstasy»). Br Med J 1992;302:697.
36. Schifano F. Chronic atypical psychosis associated with MDMA («ecstasy») abuse. Lancet 1991;338:1335.
37. Wodarz N, Boning J. «Ecstasy»-induced psychotic depersonalization syndrome. Nervenarzt 1993;64:478-80.
38. Winstock AR. Chronic paranoid psychosis after misuse of MDMA. BMJ 1991;11:1150-1.
39. Boné Pina I, Ramos Gorostiza P, Villalba Yllán P, Valle Fernández J. Trastorno psicótico persistente inducido por consumo de éxtasis (MDMA). Actas Esp Psiquiatr 2000;28:61-5.
40. Schifano F, di Furia L, Forza G. Characteristics and psychopathological consequences of MDMA («ecstasy»). Bologne International ecstasy Conference, 1996.
41. Morgan MJ. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence? Psychopharmacology (Berl) 2002;159(3):294-303.